Oncolytics Biotech Inc.
ONCY
$0.81
-$0.03-3.57%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 71.41% | 47.61% | 24.05% | -13.14% | -10.93% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 30.44% | 7.32% | 1.02% | -12.98% | -5.21% |
| Operating Income | -30.44% | -7.32% | -1.02% | 12.98% | 5.21% |
| Income Before Tax | -41.82% | -20.24% | -28.92% | -8.67% | -11.28% |
| Income Tax Expenses | -19.84% | -19.84% | -191.99% | -14.50% | 37.60% |
| Earnings from Continuing Operations | -41.56% | -20.07% | -27.73% | -8.56% | -11.37% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -41.56% | -20.07% | -27.73% | -8.56% | -11.37% |
| EBIT | -30.44% | -7.32% | -1.02% | 12.98% | 5.21% |
| EBITDA | -30.64% | -7.42% | -1.03% | 13.08% | 5.31% |
| EPS Basic | -6.82% | 6.00% | -8.10% | 2.08% | 0.47% |
| Normalized Basic EPS | -6.96% | 5.91% | -8.95% | 1.99% | 0.59% |
| EPS Diluted | -5.30% | 4.61% | -9.71% | 0.57% | -0.97% |
| Normalized Diluted EPS | -6.96% | 5.91% | -8.95% | 1.99% | 0.59% |
| Average Basic Shares Outstanding | 30.32% | 25.28% | 17.33% | 11.96% | 11.29% |
| Average Diluted Shares Outstanding | 30.32% | 25.28% | 17.33% | 11.96% | 11.29% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |